Alexander Neumeister
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexander Neumeister has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
David A. Luckenbaugh
Mood and Anxiety Disorders Program, NIMH, Bethesda, MD, USA
6 shared publicationsDennis S. Charney
Mount Sinai School of Medicine, New York, NY, USA
5 shared publicationsOmer Bonne
5 shared publicationsJohn H. Krystal
Department of Psychiatry, Yale University School of Medicine, New Haven, CT
4 shared publicationsShannan Henry
Molecular Imaging Program, Clinical Neurosciences Division, VA National Center for PTSD, VA Connecticut Healthcare System, West Haven, CT
4 shared publications- David Goldman
National Institute on Alcohol Abuse and Alcoholism
3 shared publications
Latest Publications
- 1 May 2010
- Published by Elsevier in Biological Psychiatry
- Vol. 67 (9) , 800-803
Serotonin 1B Receptor Imaging in Alcohol Dependence
- 1 May 2010
- Published by Elsevier in Biological Psychiatry
- Vol. 67 (9) , 800-803
Serotonin 1B Receptor Imaging in Alcohol Dependence
- 1 December 2009
- Published by Springer Nature in Psychopraxis
- Vol. 12 (6) , 22-26
Umgang mit dem Trauma
- 1 December 2009
- Published by Springer Nature in Psychopraxis
- Vol. 12 (6) , 22-26
Umgang mit dem Trauma
- 1 October 2009
- Published by Elsevier in Brain Research
- Vol. 1293, 13-23
Noradrenergic and serotonergic mechanisms in the neurobiology of posttraumatic stress disorder and resilience
- 1 October 2009
- Published by Elsevier in Brain Research
- Vol. 1293, 13-23
Noradrenergic and serotonergic mechanisms in the neurobiology of posttraumatic stress disorder and resilience
- 1 October 2008
- Published by Elsevier in Journal of Affective Disorders
- Vol. 110 (3) , 277-281
Plasma NPY concentrations during tryptophan and sham depletion in medication-free patients with remitted depression
- 1 October 2008
- Published by Elsevier in Journal of Affective Disorders
- Vol. 110 (3) , 277-281
Plasma NPY concentrations during tryptophan and sham depletion in medication-free patients with remitted depression
- Open Access
- 11 January 2008
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 11 (03) , 419-424
β2 Nicotinic acetylcholine receptor availability in post-traumatic stress disorder
Availability of nicotinic acetylcholine receptors containing β2 subunits (β2-nAChRs) was studied in unmedicated, symptomatic patients with post-traum
- 11 January 2008
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 11 (03) , 419-424
Open Accessβ2 Nicotinic acetylcholine receptor availability in post-traumatic stress disorder
Availability of nicotinic acetylcholine receptors containing β2 subunits (β2-nAChRs) was studied in unmedicated, symptomatic patients with post-traum
- 1 December 2006
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 26 (6) , 595-599
Cerebral Metabolic Effects of Intravenous Glycine in Healthy Human Subjects
Enhancing N-methyl-D-aspartate (NMDA) receptor function via increasing synaptic concentrations of glycine is currently investigated as a novel approach to treat schizophrenia. The neural correlates of enhanced NMDA receptor function in humans, however, are unclear to date. The present study determines the effects of intravenous administration of the glycine on regional cerebral metabolic rate of glucose (rCMRGlu) in healthy control subjects by using [18F]fluorodeoxyglucose and positron emission tomography and on neuropsychological behavioral measures. Thirteen healthy volunteers were recruited, and 12 subjects completed the protocol. These individuals participated in 1 magnetic resonance imaging study and 2 [18F]fluorodeoxyglucose positron emission tomography studies. In a double-blind, randomized, controlled, crossover design, participants received on one test day an intravenous glycine infusion and on the other test day a placebo infusion. There were no significant behavioral and neuropsychological effects of glycine compared with placebo. However, there was a significant reduction of whole-brain CMRGlu during administration of glycine compared with placebo (t = 2.60, df = 11, P = 0.023). In the a priori-selected regions of interest, there was a significant reduction in the cerebellum (t = -3.18, df = 11, P = 0.009) and the dorsolateral prefrontal cortex (t = -2.31, df = 11, P = 0.041). When corrected for whole-brain CMRGlu, rCMRGlu differences were not significant. This study suggests that studies of whole-brain cerebral metabolism may be useful for studying glycine-related mechanisms in healthy humans because there is not a clear cognitive or behavioral signal related to glycine administration at doses thought to be important clinically in patient populations.
- 1 December 2006
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 26 (6) , 595-599
Cerebral Metabolic Effects of Intravenous Glycine in Healthy Human Subjects
Enhancing N-methyl-D-aspartate (NMDA) receptor function via increasing synaptic concentrations of glycine is currently investigated as a novel approach to treat schizophrenia. The neural correlates of enhanced NMDA receptor function in humans, however, are unclear to date. The present study determines the effects of intravenous administration of the glycine on regional cerebral metabolic rate of glucose (rCMRGlu) in healthy control subjects by using [18F]fluorodeoxyglucose and positron emission tomography and on neuropsychological behavioral measures. Thirteen healthy volunteers were recruited, and 12 subjects completed the protocol. These individuals participated in 1 magnetic resonance imaging study and 2 [18F]fluorodeoxyglucose positron emission tomography studies. In a double-blind, randomized, controlled, crossover design, participants received on one test day an intravenous glycine infusion and on the other test day a placebo infusion. There were no significant behavioral and neuropsychological effects of glycine compared with placebo. However, there was a significant reduction of whole-brain CMRGlu during administration of glycine compared with placebo (t = 2.60, df = 11, P = 0.023). In the a priori-selected regions of interest, there was a significant reduction in the cerebellum (t = -3.18, df = 11, P = 0.009) and the dorsolateral prefrontal cortex (t = -2.31, df = 11, P = 0.041). When corrected for whole-brain CMRGlu, rCMRGlu differences were not significant. This study suggests that studies of whole-brain cerebral metabolism may be useful for studying glycine-related mechanisms in healthy humans because there is not a clear cognitive or behavioral signal related to glycine administration at doses thought to be important clinically in patient populations.
- Open Access
- 1 September 2006
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 63 (9) , 978-986
Differential Effects of 5-HTTLPR Genotypes on the Behavioral and Neural Responses to Tryptophan Depletion in Patients With Major Depression and Controls
Research from JAMA Psychiatry — Differential Effects of 5-HTTLPR Genotypes on the Behavioral and Neural Responses to Tryptophan Depletion in Patients With Major Depression and Controls
- 1 September 2006
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 63 (9) , 978-986
Open AccessDifferential Effects of 5-HTTLPR Genotypes on the Behavioral and Neural Responses to Tryptophan Depletion in Patients With Major Depression and Controls
Research from JAMA Psychiatry — Differential Effects of 5-HTTLPR Genotypes on the Behavioral and Neural Responses to Tryptophan Depletion in Patients With Major Depression and Controls
- 11 January 2006
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 31 (8) , 1750-1756
Effects of a α2C-Adrenoreceptor Gene Polymorphism on Neural Responses to Facial Expressions in Depression
Alterations in processing of emotionally salient information have been reported in individuals with major depressive disorder (MDD). Evidence suggests a role for noradrenaline in the regulation of a cortico-limbic-striatal circuit that has also been implicated in the pathophysiology of MDD. Herein, we studied the physiological consequences of a common coding polymorphism of the gene for the 2C-adrenoreceptor (AR) subtype—the deletion of four consecutive amino acids at codons 322–325 of the 2C-AR (2CDel322–325-AR) in medication-free, remitted individuals with MDD (rMDD), and healthy control subjects. After injection of 10 mCi of H215O, positron emission tomography (PET) measures of neural activity were acquired while subjects were viewing unmasked sad, happy, and fearful faces. The neural responses to sad facial expressions were increased in the amygdala and decreased in the left ventral striatum in rMDD patients relative to healthy control subjects. Furthermore, we report that rMDD carriers of one or two copies of the 2CDel322–325-AR exhibit greater amygdala as well as pregenual and subgenual anterior cingulate gyrus neuronal activity in response to sad faces than healthy 2CDel322–325-AR carriers and rMDD noncarriers. These results suggest that the 2CDel322–325-AR confers a change in brain function implicating this 2-AR subtype into the pathophysiology of MDD.
- 11 January 2006
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 31 (8) , 1750-1756
Effects of a α2C-Adrenoreceptor Gene Polymorphism on Neural Responses to Facial Expressions in Depression
Alterations in processing of emotionally salient information have been reported in individuals with major depressive disorder (MDD). Evidence suggests a role for noradrenaline in the regulation of a cortico-limbic-striatal circuit that has also been implicated in the pathophysiology of MDD. Herein, we studied the physiological consequences of a common coding polymorphism of the gene for the 2C-adrenoreceptor (AR) subtype—the deletion of four consecutive amino acids at codons 322–325 of the 2C-AR (2CDel322–325-AR) in medication-free, remitted individuals with MDD (rMDD), and healthy control subjects. After injection of 10 mCi of H215O, positron emission tomography (PET) measures of neural activity were acquired while subjects were viewing unmasked sad, happy, and fearful faces. The neural responses to sad facial expressions were increased in the amygdala and decreased in the left ventral striatum in rMDD patients relative to healthy control subjects. Furthermore, we report that rMDD carriers of one or two copies of the 2CDel322–325-AR exhibit greater amygdala as well as pregenual and subgenual anterior cingulate gyrus neuronal activity in response to sad faces than healthy 2CDel322–325-AR carriers and rMDD noncarriers. These results suggest that the 2CDel322–325-AR confers a change in brain function implicating this 2-AR subtype into the pathophysiology of MDD.
- 1 December 2005
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 162 (12) , 2399-b-2400
Drs. Neumeister and Manji Reply
- 1 December 2005
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 162 (12) , 2399-b-2400
Drs. Neumeister and Manji Reply
- 1 April 2005
- Published by Elsevier in Biological Psychiatry
- Vol. 57 (8) , 935-937
Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects
- 1 April 2005
- Published by Elsevier in Biological Psychiatry
- Vol. 57 (8) , 935-937
Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects